Biotech - Spark Newswire

2 minute read

TC BioPharm Announces Publication Of Paper In AML Research Highlighting The Company’s Development Of Allogeneic Gamma-Delta T Cell Therapies

Today, 6:41 PM

TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer,

TCBP

1 minute read

Aileron Therapeutics Announces Termination Of Phase 1b Breast Cancer Chemoprotection Trial And Exploration Of Strategic Alternatives

By Bill Haddad

Today, 6:41 PM

Aileron Therapeutics (NASDAQ:ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial

ALRN

4 minute read

Yield10 Bioscience Announces Key Advancements In The Development Of Herbicide Tolerant Camelina Supporting Large Acreage Production Of Low-Carbon Intensity Feedstock Oil For The Biofuel Market

By Happy Mohamed

Today, 6:41 PM

-Second field trial confirms Camelina tolerance to over-the-top herbicide application -Greenhouse studies support proof-of-concept for stacked herbicide traits in Camelina -Yield10 filed RSR under USDA-APHIS's

YTEN

1 minute read

89bio To Present Additional Pegozafermin Data In Severe Hypertriglyceridemia From Phase 2 ENTRIGUE Study At American College Of Cardiology’s Annual Scientific Session Together With World Congress Of Cardiology

By Happy Mohamed

Today, 6:41 PM

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today

ETNB

2 minute read

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

By Vandana Singh

Today, 6:41 PM

The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…

CSLLY

1 minute read

Akebia Therapeutics Received Interim Response From The FDA To Appeal For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease

By Happy Mohamed

Today, 6:41 PM

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim

AKBA

1 minute read

FDA
News

Regeneron Says Pozelimab (C5 Antibody) BLA For Treatment Of Children And Adults With Ultra-rare CHAPLE Disease Accepted For FDA Priority Review

By Benzinga Newsdesk

Today, 6:41 PM

Regeneron announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pozelimab as a treatment for adults and children as young as 1 year of age with

REGN

1 minute read

Takeda Earlier Announced Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

By Benzinga Newsdesk

Today, 6:41 PM

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT. No New Safety Signals Were Seen

TAK

1 minute read

The FDA Has Completed A Filing Review Of Valneva’s Biologics License Application For Its Single-shot Chikungunya Vaccine Candidate, VLA1553

By Benzinga Newsdesk

Today, 6:41 PM

VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023.

VALN

1 minute read

Medicinova Presented New Data Regarding Tumor Tissue Analysis And Clinical Outcome From A Glioblastoma Clinical Trial, MN-166-GBM-1201 Phase 1/2 Study

By Benzinga Newsdesk

Today, 6:41 PM

Tumor tissues were analyzed to determine potential predictors of treatment response to MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Pre-treatment tumor tissues were obtained from the resected

MNOV